cbdMD (YCBD) Net Income towards Common Stockholders (2016 - 2026)
cbdMD (YCBD) posted Net Income towards Common Stockholders of -$324602.0 for Q4 2025, up 52.26% sequentially from -$679968.0 in Q3 2025, and up 67.06% YoY from -$194303.7 in Q4 2024.
cbdMD (YCBD) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
cbdMD has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$324602.0 in Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 67.06% year-over-year to -$324602.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.7 million (up 44.5% YoY) and the FY2025 annual result came in at -$4.4 million, up 43.21% from the prior year.
- Net Income towards Common Stockholders grew to -$324602.0 in Q4 2025 per YCBD's latest filing, from -$679968.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $977007.0 in Q2 2021 and troughed at -$32.6 million in Q2 2022.
- A 5-year average of -$6.5 million and a median of -$2.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2021 and 2022: Net Income towards Common Stockholders soared 110.79% in 2021, then sank 3440.27% in 2022.
- Over 5 years, Net Income towards Common Stockholders stood at -$20.2 million in 2021, then soared by 75.42% to -$5.0 million in 2022, then soared by 59.71% to -$2.0 million in 2023, then jumped by 50.66% to -$985406.0 in 2024, then jumped by 67.06% to -$324602.0 in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$324602.0, -$679968.0, and -$1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | -1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.20 Mn |
| Dec 31, 2025 | -324,602.00 |
| Sep 30, 2025 | -679,968.00 |
| Jun 30, 2025 | -1.23 Mn |
| Mar 31, 2025 | -1.48 Mn |
| Dec 31, 2024 | -985,406.00 |
| Sep 30, 2024 | -1.16 Mn |
| Jun 30, 2024 | -540,763.00 |
| Mar 31, 2024 | -4.01 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Sep 30, 2023 | -16.88 Mn |
| Jun 30, 2023 | -2.77 Mn |
| Mar 31, 2023 | -2.34 Mn |
| Dec 31, 2022 | -4.96 Mn |
| Sep 30, 2022 | -15.63 Mn |
| Jun 30, 2022 | -32.63 Mn |
| Mar 31, 2022 | -5.66 Mn |
| Dec 31, 2021 | -20.16 Mn |
| Sep 30, 2021 | -4.36 Mn |
| Jun 30, 2021 | 977,007.00 |